
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing curcumin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing curcumin is listed. Products containing it are filed in the directory as homeopathic products, in liquid form. None of the listed products containing curcumin is in gel form.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Curcumin is a plant polyphenol from turmeric that compounding pharmacies prepare as oral capsules and topical preparations by prescription.
Curcumin is the main natural polyphenol in the root of the turmeric plant (Curcuma longa) and gives the spice its yellow color. Laboratory research describes antioxidant and anti-inflammatory activity, including blocking the inflammatory signal NF-kB, but the National Center for Complementary and Integrative Health states there is not enough evidence to conclude that turmeric or curcumin is beneficial for any health purpose. Curcumin is sold mainly as a dietary supplement, and curcuminoids are recognized by FDA as generally recognized as safe (GRAS) as a food ingredient. FDA has stated there are no FDA-approved curcumin products for injection. A prescriber may order curcumin compounded as a capsule or topical preparation in a vehicle or combination not available as a supplement. Compounded preparations are not FDA-approved and require a prescription.
Because curcumin has no FDA drug label, there is no boxed warning. NCCIH reports liver damage in some people using highly bioavailable curcumin formulations; stop and contact your prescriber for fatigue, nausea, poor appetite, dark urine or yellowing of the skin or eyes. Oral turmeric can cause nausea, reflux, stomach upset, diarrhea or constipation, and topical curcumin can cause hives, itching or contact dermatitis. LactMed notes that turmeric may raise bleeding risk with warfarin and antiplatelet drugs, so tell your prescriber or pharmacist about every medicine you take. In 2017 FDA investigated a death and a serious allergic reaction after intravenous infusion of a compounded curcumin emulsion; FDA noted that the safety of IV curcumin has not been established. NCCIH says turmeric supplements may be unsafe during pregnancy, and safety above food amounts while breastfeeding is not well established. For any side effect, talk to your prescriber or pharmacist.
Curcumin is a curcuminoid polyphenol whose two primary proposed mechanisms are antioxidant and anti-inflammatory, including inhibition of NF-kB activation. Oral bioavailability is poor, which a peer-reviewed review attributes to poor absorption, rapid metabolism and rapid elimination; coadministration with piperine from black pepper increases exposure, and NCCIH links liver injury reports to highly bioavailable formulations. There are no labeled indications to cite; FDA has stated there are no FDA-approved curcumin products for injection. NCCIH describes early positive but inconclusive evidence for oral use in osteoarthritis, unclear findings for topical use in knee osteoarthritis, and early findings in oral mucositis and fatty liver disease. In 2017 a compounded curcumin emulsion given intravenously was associated with a fatal cardiac arrest and a hypersensitivity reaction; FDA found diethylene glycol in the ungraded PEG 40 castor oil used and said there is little to no toxicologic or clinical information on the safety of IV curcumin. Dosing per prescriber. Monitor for hepatotoxicity symptoms, bleeding with anticoagulant or antiplatelet therapy, and GI or skin reactions. Curcumin is not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)